Vimarsana
Biggest News Aggregation in the World

Page 2 - Multiple System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple System Atrophy Today - Breaking & Trending Today

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia - Vimarsana News

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Published: April 29, 2024

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 -- Alterity Therapeutics , a...

Source: marketscreener.com
Related Topics:
United StatesSan FranciscoRemy BernardaHannah HowlettDavid StamlerNational Institute Of Neurological DisordersNational Institutes Of HealthAlterity TherapeuticsEuropean CommissionSecurities ExchangeWorld Orphan Drug Congress United StatesNew Evidence IndicatesIron ChaperoneRedistribute IronUnique Iron Targeting DrugTreating FriedreichAshley PallPharmaceutical SciencesWayne StateChief Executive OfficerMultiple SystemMultiple System AtrophyNational InstitutesNational InstituteNeurological Disorders
The future of gene therapy has arrived, and it's changing lives for the better - Vimarsana News

The future of gene therapy has arrived, and it's changing lives for the better

Published: April 22, 2024

Ohio State University's Wexner Medical Center research is exploring the field of gene therapy to help people with rare genetic disorders.

Source: hometownstations.com
Related Topics:
United StatesKrystof BankiewiczArcelia RamirezDelilah RamirezRare Diseases Information CenterCollege Of MedicineOhio State Gene Therapy InstituteUniversity Of California San FranciscoParkinson FoundationOhio State University Wexner Medical CenterWexner Medical CenterOhio State Wexner Medical CenterWorld Health OrganizationOhio StateCalifornia San FranciscoWorld HealthRare Diseases InformationOhio State Wexner MedicalOhio State Gene TherapyMultiple System AtrophyThe Ohio State University Wexner Medical CenterGene Therapy
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - Vimarsana News

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Published: April 18, 2024

BOSTON and ATLANTA, April 18, 2024 -- Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's...

Source: marketscreener.com
Related Topics:
United StatesMiltonh WernerAlex LoboInhibikase Or CompanySternir IncExchange CommissionInstitute Of The National Institutes HealthNational Institute Of Neurological DiseaseCompany ContactDrug Administration For IkInhibikase Therapeutics IncAbelson Tyrosine KinasesFellow ShareholdersInhibikase TherapeuticsDrug AdministrationMultiple System AtrophyNational InstituteNeurological DiseaseNational InstitutesPulmonary Arterial HypertensionAbelson Tyrosine KinaseAbelson TyrosinePrivate Securities Litigation Reform Act
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 - Vimarsana News

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Published: April 10, 2024

DUBLIN, April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio...

Source: marketscreener.com
Related Topics:
United StatesTheravance BiopharmaRhonda FarnumItalo BiaggioniHoracio KaufmannFeliciab AxelrodRick WinninghamTheravance Biopharma IncDysautonomia CenterVanderbilt Autonomic Dysfunction CenterYork University Grossman School Of MedicinePrnewswire Theravance Biopharma IncNeurological InstituteDivision Of Autonomic DisordersLangone HealthNational Institute Of Neurological DisordersMovement Disorders SocietyClinical Autonomic ResearchNew York University Grossman SchoolPharmacology DirectorRaine MillerChief Business OfficerAxelrod ProfessorAutonomic DisordersPure Autonomic Failure
Alterity Therapeutics to Present New Data on ATH434 at the - Vimarsana News

Alterity Therapeutics to Present New Data on ATH434 at the

Published: April 10, 2024

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...

Source: globenewswire.com
Related Topics:
United StatesSan FranciscoRemy BernardaDanielo ClaassenMargaret BradburyDavid StamlerDaniel ClaassenHannah HowlettDepartment Of Pharmaceutical SciencesNonclinical DevelopmentEuropean CommissionAlterity TherapeuticsWorld Orphan Drug Congress United StatesAmerican Academy Of NeurologyWayne State UniversityNational Institute Of HealthVanderbilt University Medical CenterParkinson FoundationUnique Iron Targeting DrugTreating FriedreichPharmaceutical SciencesWayne StateAmerican AcademyNovel InhibitorSynuclein Aggregation